Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cyclophosphamide 2umbralisib 1ublituximab 1prednylidene 1fludarabine phosphate 1epratuzumab 1deltacortene 1cc-486 1Whole-Body Irradiation 1Vincristine 1Thiotepa 1Specimen Handling 1Rituximab 1Radioimmunodetection 1Prednisone 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Etoposide 1Doxorubicin 1Carboplatin 1CT-P10 1Busulfan 1Bendamustine Hydrochloride 1Azacitidine 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Lymphoma, B-Cell, Marginal Zone × Hyaluronoglucosaminidase × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡